Table 4.
Crude | Adjusteda | Adjustedb | ||||
---|---|---|---|---|---|---|
Standardized β | P -value | Standardized β | p-value | Standardized β | p-value | |
Age | 0.635 | <0.001* | 0.492 | <0.001* | 0.467 | <0.001* |
Gender | −0.172 | 0.079 | −0.019 | 0.654 | −0.013 | 0.691 |
BSA (g/m2) | 0.27 | 0.187 | 0.031 | 0.238 | 0.345 | 0.459 |
Hemoglobin (g/L) | −0.150 | 0.131 | −0.059 | 0.481 | −0.098 | 0.221 |
Hyperlipidemia | 0.242 | 0.013* | 0.118 | 0.144 | 0.065 | 0.433 |
Peripheral systolic BP (mmHg) | 0.397 | <0.001* | 0.185 | 0.024* | 0.169 | 0.059 |
Diabetes (%) | 0.589 | <0.001* | 0.555 | <0.001* | 0.532 | <0.001* |
Hypertension (%) | 0.308 | <0.001* | 0.294 | 0.013* | 0.158 | 0.050* |
BMI (g/m2) | 0.055 | 0.579 | −0.156 | 0.063 | −0.133 | 0.118 |
eGFR (mL/min/1.73 m2) | −0.410 | <0.001* | −0.259 | 0.003* | −0.234 | 0.008* |
Echocardiographic parameters | ||||||
Simpsons biplane EF(%) | −0.117 | 0.237 | −0.036 | 0.646 | −0.094 | 0.634 |
TDI S’ - septal (cm/s) | 0.186 | 0.03 * | 0.120 | 0.058 | 0.101 | 0.093 |
E/e’(average) | 0.387 | <0.001* | 0.192 | 0.022* | 0.113 | 0.089 |
LVMI (g/m2) | 0.379 | <0.001* | 0.165 | 0.03* | 0.143 | 0.042* |
LV Twist(°) | 0.388 | 0.003* | 0.181 | 0.019* | 0.163 | 0.025* |
GLS(%) | 0.300 | 0.01* | 0.186 | 0.09 | 0.060 | 0.130 |
GCS(%) | 0.046 | 0.197 | 0.018 | 0.458 | 0.010 | 0.634 |
Standardized coefficients (β) refer to how many SDs a dependent variable (aPWV) will change, per standard deviation increase in the predictor variable. n = 106
*statistically significant
CKD chronic kidney disease; BSA body surface area; BP blood pressure; LVMI left ventricular mass index; eGFR estimated glomerular filtration rate; EF ejection fraction; LV left ventricular
aAdjusted for age, gender, diabetes, SBP, BMI, treated hyperlipidaemia, eGFR and family history of ischaemic heart disease
bAdjusted for factors in Model 2 plus antihypertensive medication (b-blockers, dihydropyridine calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers) and prednisolone